๐ Novo Nordisk $NVO drops -6% โ guidance disappoints as GLP-1 growth slows
Novo Nordisk fell roughly 6% Wednesday after the Danish pharma giant's 2026 outlook underwhelmed investors โ the company hiked its forecast but warned adjusted sales at constant exchange rates could decline as much as 6%. That's a tough pill for a stock that has ridden Ozempic and Wegovy demand for years. Meanwhile, crosstown rival Eli Lilly is surging today after its own blockbuster quarter. Is NVO a buy-the-dip opportunity or is the GLP-1 growth story fading? Not financial advice.
โก 54 buzzing
372 views
๐ 0 subscribed
